<DOC>
	<DOCNO>NCT01553357</DOCNO>
	<brief_summary>This open label , multicenter , exploratory , single arm , two-stage study aim explore efficacy safety lenalidomide dexamethasone combination ( LD ) first line therapy previously untreated patient primary Plasma Cell leukemia ( PPCL ) .</brief_summary>
	<brief_title>Lenalidomide Dexamethasone Primary Plasma Cell Leukemia</brief_title>
	<detailed_description>The primary endpoint response rate accord International Uniform Criteria ; secondary endpoint : ) time progression ( TTP ) , progression free survival ( PFS , overall survival ( OS ) ; ii ) percentage eligible PPCL patient able mobilize collect peripheral blood stem cell LD treatment ; iii ) percentage eligible PPCL patient able undergo autologous allogeneic stem cell transplantation LD treatment ; iv ) serious/severe adverse event ( SAEs ) rate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnose patient fulfil IMWG diagnostic criterion PPCL Age &gt; 18 year ECOG performance status 0,1 2 Life expectancy least 12 week Myocardial infarction within 6 month prior enrollment uncontrolled angina Severe uncontrolled ventricular arrhythmia ECG evidence acute ischemia active conduction system abnormalities Female subject either pregnant breastfeeding Serious medical psychiatric illness Total bilirubin great 2.0 mg/dL and/or SGOT SGPT great two half time normal ( unless due primary malignancy ) History severe hepatic dysfunction Active infection HIV positivity Uncontrolled insulindependent diabetes mellitus Uncompensated major thyroid adrenal dysfunction Hemodialysis peritoneal dialysis Renal dysfunction ( unless due primary malignancy ; case , enrollment discretion principal investigator ) ECOG performance status 3 ( unless due primary malignancy ; case , enrollment discretion principal investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Plasma cell leukemia</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Stem cell transplantation</keyword>
</DOC>